Reasons to buy
Each comprehensive publication provides unrivalled depth and insight into each complex disease area:
- A groundbreaking compilation of all the major health technology assessments (HTA) and pricing and reimbursement reviews
- Market access roadmaps based on country specific Strategic Insights summarised at the start of each chapter in addition to the Executive Summary
- Authored by writers who have significant experience of clinical development, having brought products to market from phase II, successfully taken products through HTA and pricing and reimbursement and who have been members of HTA bodies
- Independent external validation by payers and KOLs.
- Area to watch: As a new feature, issues that could affect strategy development and that need to be monitored are flagged as Areas to watch.
To find out more or register your disease area interest, click here
Fill in the fields below and press submit. A member of our team
will respond
shortly.